Zhidan Liu

Dr. Zhidan Liu

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2022 in Journal of Integrative Medicine
Verified
Journal Article
Closed access
CZChuang Zhao
Chuang Zhao
XLXiao-Yan Li
Xiao-Yan Li
ZLZun-Yuan Li
Zun-Yuan Li
MLMiao Li
Miao Li
ZLZhidan Liu
Zhidan Liu

30 July 2024 in Cureus
Verified
Journal Article
Open access
YMYe-Ran Mao
Ye-Ran Mao
LZLing-Yi Zhu
Ling-Yi Zhu
RDRuo-Fei Du
Ruo-Fei Du
XLXiao-Yu Liu
Xiao-Yu Liu
ZLZhidan Liu
Zhidan Liu
LLLi Li
Li Li
Background and objectives: In ancient China, bee venom was widely used to treat various diseases. Although using bee venom is not currently a mainstream medical method, some have applied it to treat certain conditions, including idiopathic facial paralysis (IFP). Recently, melittin (Mel), the main active component of bee venom, has been shown strong anti-inflammatory and analgesic effects. However, how bee venom improves neurological dysfunction in facial paralysis remains unknown. This study aimed to investigate the anti-neurotraumatic effect of Mel on Schwann cells (SCs), the main cells of the neuron sheath, injured by oxidative stress. Methods: A model of hypoxic SCs was established, and CCK-8 assay, siRNA transfection, enzyme-linked immunosorbent assay, quantitative reverse transcription-polymerase chain reaction, western blot, immunofluorescence, and cell ultrastructure analyses were conducted to investigate the mitigation of hypoxia-induced damage to SCs in vitro, revealing the effects of Mel on oxidative stress injury in SCs. Results: The overexpression of HIF-1 alpha in CoCl2-induced SCs (p < 0.05) indicated the establishment of an SCs hypoxia model. The proliferation and regeneration process of the hypoxic SCs enhanced in the Mel-treated group compared to the CoCl2 group has been proven through the CCK-8 experiment (p < 0.0001) and S-100 mRNA expression detection (p < 0.0001). The increased level of reactive oxygen species (ROS) (p < 0.001) and decreased superoxide dismutase (SOD) levels (p < 0.05) in the CoCl2-induced SCs indicated that Mel can alleviate the oxidative stress damage to SCs induced by CoCl2. Mel alleviated oxidative stress and inflammation in hypoxic SCs by reducing pro-inflammatory cytokines IL-1 beta (p < 0.0001) and TNF-alpha (p < 0.0001). In addition, Mel augmented cellular vitality and regulated indicators related to oxygen metabolism, cell repair, neurometabolism, and vascular endothelial formation after hypoxia, such as C-JUN (p < 0.05), glial cell line-derived neurotrophic factor (GDNF; p < 0.001), vascular endothelial growth factor (VEGF; p < 0.05), hypoxia-inducible factor 1-alpha (HIF-1 alpha; p < 0.05), interleukin-1 receptor type 1 (IL-1R1; p < 0.05), enolase1 (ENO1; p < 0.05), aldose reductase (AR; p < 0.01), SOD (p < 0.05), nerve growth factor (NGF; p < 0.05), and inducible nitric oxide synthase (iNOS; p < 0.05). In terms of its mechanism, Mel inhibited the expression of proteins associated with the NF-kappa B pathway such as IKK (p < 0.01), p65 (p < 0.05), p60 (p < 0.001), IRAK1 (p < 0.05), and increased IKB-alpha (p < 0.0001). Moreover, knocking out of IL-1R1 in the si-IL-1R1 group enhanced the therapeutic effect of Mel compared to the Mel-treated group (all of which p < 0.05). Conclusion: This research provided evidence of the substantial involvement of IL-1R1 in oxidative stress damage caused by hypoxia in SCs and proved that Mel alleviated oxidative stress injury in SCs by targeting IL-1R1 to downregulate the NF-kappa B-mediated inflammatory response. Mel could potentially serve as an innovative therapeutic approach for the treatment of IFP.

22 April 2016 in Nucleosides, Nucleotides & Nucleic Acids
Verified
Journal Article
Closed access
VGVinay Girijavallabhan
Vinay Girijavallabhan
AAAshok Arasappan
Ashok Arasappan
FBFrank Bennett
Frank Bennett
KCKevin Chen
Kevin Chen
QDQun Dang
Qun Dang
FNF. George Njoroge
F. George Njoroge
Novel 2′-modified guanosine nucleosides were synthesized from inexpensive starting materials in 7–10 steps via hydroazidation or hydrocyanation reactions of the corresponding 2′-olefin. The antiviral effectiveness of the guanosine nucleosides was evaluated by converting them to the corresponding 5′-O-triphosphates (compounds 38–44) and testing their biochemical inhibitory activity against the wild-type NS5B polymerase.

22 August 2025 in Turkish Journal of Physical Medicine and Rehabilitation
Verified
Journal Article
Open access
YMYe-Ran Mao
Ye-Ran Mao
WFWenjun Fan
Wenjun Fan
YZYinjie Zhu
Yinjie Zhu
QGQing Gu
Qing Gu
QJQuanfang Jin
Quanfang Jin
ZLZhidan Liu
Zhidan Liu
Objectives: The objective of study was to compare the effects of pelvic myofascial trigger point release and structured pelvic floor muscle training (PFMT) in patients with female sexual dysfunction after vaginal delivery. Patients and methods: In this prospective randomized controlled trial, 126 patients with female sexual dysfunction after vaginal delivery were included between October 2022 and December 2023. The participants were randomly allocated to receive either trigger point release and structured PFMT (63 females; mean age, 30.4±2.8 years; range, 25 to 35 years) or only structured PFMT (63 females; mean age, 31.4±3.1 years; range, 24 to 35 years). The primary outcome was Female Sexual Function Index (FSFI) score of the participants. Secondary outcomes were Glazer pelvic floor electromyography and the Visual Analog Scale score of urogenital pain map, pelvic floor muscle pain map, and bladder pain map. Results: The observation group manifested a significant improvement in the FSFI total score and each individual subitem compared to the control group (p<0.01). In addition, in Glazer pelvic floor electromyography, the observation group exhibited a significant decrease in pre-resting value and post-resting value compared to the control group after treatment (p<0.01). Additionally, there was significant decrease in Visual Analog Scale scores in the observation group compared to the control group (p<0.01). Moreover, after therapy, the observation group demonstrated a significantly greater enhancement in pelvic floor muscle strength than the control group (p<0.05). Conclusion: Pelvic myofascial trigger point release combined with structured PFMT is an efficient treatment for female sexual dysfunction after vaginal delivery compared to structured PFMT alone.

10 October 2025 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
XLXiaoyu Liu
Xiaoyu Liu
YMYeran Mao
Yeran Mao
RDRuofei Du
Ruofei Du
ZLZhidan Liu
Zhidan Liu
The underlying mechanism of how natural musk treats Bell's palsy is not clear. This study aims to reveal the potential mechanism of musk in treating peripheral nerve injury in vitro. To achieve this, an oxidative stress injury model was established in Schwann cells (SCs) using cobalt chloride (CoCl2). To assess the protective effects of Muscone (Mus) on this injury and explore its mechanism, cell viability assays, siRNA transfection, enzyme-linked immunosorbent assays (ELISA), quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blotting, immunofluorescence staining, and ultrastructural analysis of cells were employed. As a result, it is indicated that Mus intervention enhanced SC proliferation and S-100b mRNA under hypoxia, while also reducing reactive oxygen species (ROS) and elevating superoxide dismutase (SOD) levels. Mus ameliorated oxidative stress and inflammation in hypoxic SCs by reducing IL-1β and TNF-α. Furthermore, Mus modulated key indicators involved in oxygen metabolism, cell repair, and neurometabolism, including C-JUN and GDNF. IL-1R1, localized to the SC membrane, was upregulated by hypoxia but significantly downregulated following Mus intervention. Mus also inhibited the expression of NF-κB pathway components (IRAK1, IKK, p65, p50) and increased IκB-α. Critically, abolishing IL-1R1 expression via siRNA knockdown showed a consistent effect with Mus. It is concluded that by suppressing IL-1R1, Mus attenuated inflammation in hypoxic SCs through inhibition of the NF-κB pathway. This study indicated IL-1R1's role in hypoxia-induced SC dysfunction. Furthermore, Mus might be a potentially effective medicinal for treating Bell's palsy.

15 April 2025 in Integrative Medicine Research
Verified
Journal Article
Open access
ZLZun-Yuan Li
Zun-Yuan Li
CCChun-Lan Chen
Chun-Lan Chen
XLXiao-Yan Li
Xiao-Yan Li
WHWen-Ge Huo
Wen-Ge Huo
YYYan Yang
Yan Yang
ZLZhidan Liu
Zhidan Liu
Moxibustion has been applied in various clinical treatments, including chemotherapy-induced leukopenia. Using a Bayesian network meta-analysis, this study assessed a wide range of published data to identify the most efficient and effective method of moxibustion therapy for treating chemotherapy-induced leukopenia. PubMed, EMBASE, and eight other databases plus two clinical trial registration platforms were searched from their respective inception date to January 2024. All randomized controlled trials (RCTs) of moxibustion for chemotherapy-induced leukopenia were included. The primary outcome indicator was white blood cell count, and the secondary outcome was the Karnofsky performance status score. Stata (version 17.0) and the gemtc package (version 1.0-0) of R (version 4.3.1) were used to perform the network meta-analysis. Thirty RCTs with 2282 total patients involving 12 types of moxibustion-related therapies were identified. Results of the surface under the cumulative ranking curve revealed the following treatments as most effective for leukopenia: thunder-fire moxibustion combined with medication (95.9 %), grain-sized moxibustion combined with medication (76.2 %), and herb-separated moxibustion (76.0 %). Grain-sized moxibustion combined with medication (76.5 %) ranked first in improving Karnofsky performance status scores. Thunder-fire moxibustion combined with medication appears to be the most effective treatment for chemotherapy-induced leukopenia. This study is registered in the International Prospective Register of Systematic Reviews (PROSPERO) database, registration number CRD42023402588.